GlaxoSmithKline: The drug Exdensur has been approved in China for the treatment of chronic sinusitis with nasal polyps.

On April 8th, GlaxoSmithKline stated that the China National Medical Products Administration has approved Exdensur as an adjuvant therapy for the treatment of adult patients with chronic rhinosinusitis with nasal polyps who have not been adequately controlled with systemic corticosteroids or surgery.